Home Diaspora Nigeria must break barriers to scale health innovations – NAPPSA President

Nigeria must break barriers to scale health innovations – NAPPSA President

0
83

 

Nigeria must break barriers to scale health innovations - NAPPSA President
NAPPSA President and distinguished guest at the 20th Annual Scientific Conference & Exposition.

Pharm. (Dr) Adekunle Tometi is the president of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas (NAPPSA). In this Diaspora edition, he discusses key outcomes of the association’s recently concluded 20th Annual Scientific Conference and Expo, held at the Hyatt Regency Aurora-Denver Conference Centre in Aurora, Colorado, USA. Drawing the attention of the Nigerian government to the bottlenecks hindering the scaling up of healthcare innovations, he stresses the urgency of addressing them to achieve meaningful healthcare reforms. He also highlights the need for Nigeria to develop structured collaboration platforms that will enable stakeholders, including pharmacists, researchers, industry leaders, policymakers and technology developers, to work together to meet patients’ needs. Excerpts:

Congratulations on your successful 20th Annual NAPPSA Scientific Conference and Expo. From the theme of the conference, “Globalising Innovations in Healthcare: Bridging Science, Access and Impact”, what are the biggest barriers preventing healthcare innovations from moving from scientific discovery to widespread use, particularly in Nigeria?

 

Nigeria must address barriers preventing health innovations from moving into widespread use. The core barriers are fragmented systems, weak translational pathways, regulatory delays, inadequate manufacturing capacity, and limited investment in implementation science.

From the conference deliberations, several themes emerged. While Nigeria has brilliant scientists and innovators, the journey from discovery to widespread use is slowed by weak translational research infrastructure – discoveries rarely progress into prototypes, clinical validation, or commercialisation; regulatory bottlenecks – approval timelines for diagnostics, digital tools, and therapeutics remain slow and unpredictable; limited local manufacturing capacity, forcing reliance on imports and slowing adoption of new technologies; poor integration between academia, industry, and practice – innovations remain siloed; insufficient funding for scale-up and implementation science. Nigeria invests heavily in discovery but minimally in adoption pathways.

NAPPSA 2026 highlighted that innovation is not the challenge – translation is. How can Nigeria strengthen collaboration among pharmacists, researchers, pharmaceutical industries, policymakers and technology developers to ensure that locally developed healthcare innovations reach the patients who need them?

 

Nigeria needs structured collaboration platforms, shared innovation hubs, and policy-driven incentives that force cross-sector engagement. Key strategies include national innovation consortia that link universities, teaching hospitals, pharmaceutical manufacturers, and tech companies; pharmacy-led translational hubs modelled after NAPPSA’s diaspora networks, where pharmacists serve as the bridge between science and patient care; government-mandated multi-stakeholder review boards for new technologies, ensuring early alignment between regulators, industry, and innovators; joint funding schemes where government provides seed funding and industry provides scale-up capital; as well as diaspora–Nigeria innovation pipelines leveraging NAPPSA’s expertise to support mentorship, regulatory navigation, and commercialisation. To achieve all these strategies, collaboration must be institutionalised, not voluntary.

It has been observed that access remains a major challenge in healthcare, especially for patients in low- and middle-income countries.

 

What strategies should Nigeria adopt to make innovative medicines, diagnostics and digital health solutions both accessible and affordable?

Nigeria must combine policy reform, local manufacturing, reimbursement innovation, and digital infrastructure expansion. NAPPSA 2026 emphasised several actionable strategies, including: Expand local manufacturing through tax incentives, technology transfer agreements, and diasporasupported GMP training; adopt valuebased reimbursement models, so innovative therapies are covered based on outcomes, not cost alone; strengthen NHIA coverage for diagnostics, chronic disease management tools, and digital health services; invest in digital infrastructure -broadband access, interoperable health records, and telehealth reimbursement; bulk procurement and pooled purchasing for innovative medicines to reduce cost; public–private partnerships to subsidise highimpact technologies used in everyday diagnostic, testing, and AIenabled tools. Nigeria must treat access as a policy priority, not an afterthought.

 

What role can Nigerian pharmacists and pharmaceutical scientists play in global health innovation, rather than simply adopting innovations developed in other countries?

Nigerian professionals must shift from consumers of innovation to co-creators and global contributors. NAPPSA 2026 showcased how Nigerian pharmacists can lead globally by driving practice-based research in community and hospital settings; participating in global clinical trials through diaspora-supported site development; developing context-specific digital health tools for chronic disease management, maternal health, and infectious diseases; leading pharmacovigilance and realworld evidence generation across Africa; and contributing to global manufacturing and supply chain resilience through Nigeria’s emerging pharmaceutical industrial zones.

Pharmacists are uniquely positioned because they sit at the intersection of science, patient care, and policy.

 

How important is investment in research and development to Nigeria’s ability to develop home-grown healthcare solutions, and what changes are needed in government and private-sector funding of health research?

Nigeria must triple its R&D investment, diversify funding sources, and create incentives for private-sector participation. Key changes needed include: Increase national R&D spending from <0.5 per cent of GDP to at least 2 per cent over five years; create competitive grant programmes for translational research, not just academic studies; offer tax credits for pharmaceutical companies investing in R&D; establish innovation funds jointly financed by government, banks, and private investors; and support diasporaled research collaborations through NAPPSA and similar bodies. R&D is the foundation of homegrown innovation. Without investment, Nigeria will remain dependent on imports.

 

As artificial intelligence, digital health, precision medicine and other emerging technologies transform healthcare, how can Nigeria embrace these innovations while addressing concerns around regulation, patient safety, data protection and health inequities?

Nigeria must adopt a “responsible innovation” framework: embracing new technologies while protecting patients. NAPPSA 2026 emphasised developing national AI and digital health regulations aligned with global standards; strengthening data protection laws and enforcing compliance in healthcare settings; training pharmacists and clinicians in AI literacy, digital therapeutics, and genomic medicine; ensuring equitable access by subsidising digital tools for rural and underserved populations; creating regulatory sandboxes where innovators can test technologies under supervision; and building national health data repositories with strict governance. Nigeria must innovate with guardrails.

 

Looking ahead, what measurable impact would you like to see from the globalisation of healthcare innovations in Nigeria, and what should the government, professional bodies and industry do now to make that impact a reality?

Nigeria should aim for measurable improvements in access, outcomes, manufacturing capacity, and global competitiveness. Desired measurable impacts include reduced diagnostic delays for cancer, infectious diseases, and chronic conditions; increased local manufacturing of essential and innovative medicines; expanded NHIA coverage for digital health and precision medicine; improved patient outcomes through AIenabled decision support; greater participation in global clinical trials and research networks; and stronger export capacity for Nigerian pharmaceutical products.

To achieve this, government, professional bodies, and industry must implement a national innovation roadmap aligned with NAPPSA’s diaspora expertise; invest in infrastructure – labs, manufacturing plants, digital networks; reform regulatory processes for speed, transparency, and innovation-friendliness; support workforce development through continuous professional training; and create incentives for private-sector investment in R&D and manufacturing. Nigeria must move from aspiration to execution.

LEAVE A REPLY

Please enter your comment!
Please enter your name here